Rachael Natrajan

Institute of Cancer Research — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

66h-index15.3kcitations380works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(102), Chromatin Remodeling and Cancer(50), Breast Cancer Treatment Studies(46), Cancer Mechanisms and Therapy(36), BRCA gene mutations in cancer(35)

Publications380 total

FAK Inhibition Remodels the Metastatic ECM and Restores CD8⁺ T Cell Trafficking and Immunosurveillance
2026
Tracing the evolutionary trajectory of CDK4/6 inhibitor resistance in oestrogen receptor positive breast cancer
2025Open Access
Dysregulated <i>SASS6</i> expression promotes increased ciliogenesis and cell invasion phenotypes
Life Science Alliance·2025Open Access
Clinical challenges and proposed solutions for patients with invasive lobular breast cancer
Annals of Oncology·2025· 1 citedOpen Access
Multimodal profiling unveils a reversible breast basal-like cell state in AKT-inhibitor resistant tumours
2025Open Access
Proteogenomic discovery of <i>RB1</i> -defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets
Science Advances·2025· 4 citedOpen Access
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma
Oncogene·2025· 7 citedOpen Access
Abstract PO4-13-11: Epigenetically defined sub-clonal heterogeneity drives therapy resistance in triple-negative breast cancer
Cancer Research·2024· 1 cited
Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer
British Journal of Cancer·2024· 4 citedOpen Access
Basal–epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer
EMBO Molecular Medicine·2024· 16 citedOpen Access
Abstract B059: Epigenetically defined sub-clonal heterogeneity drives therapy resistance in triple-negative breast cancer
Cancer Research·2024· 1 cited
Abstract B058: Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER+ breast cancer
Cancer Research·2024
Dysregulated <i>SASS6</i> expression promotes increased ciliogenesis and cell invasion phenotypes
2024· 1 citedOpen Access
Abstract B020: <i>SF3B1 </i>hotspot mutations confer sensitivity to PARP inhibition through a defective replication stress response
Molecular Cancer Therapeutics·2023
61P Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER+ breast cancer
ESMO Open·2023Open Access
Evolutionary determinants of curability in cancer
Nature Ecology & Evolution·2023· 10 cited
Implications of tumour heterogeneity on cancer evolution and therapy resistance: lessons from breast cancer
The Journal of Pathology·2023· 8 citedOpen Access
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response
Nature Genetics·2023· 40 citedOpen Access
Supplementary Table S2 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
2023Open Access
Press Conference from Functional Viability Profiles of Breast Cancer
2023Open Access
page 1 of 19Next →

Frequent Co-authors

Jorge S. Reis‐Filho(38), Alan Mackay(26), Britta Weigelt(17), Maryou B. Lambros(16), Alan Ashworth(15), Christopher J. Lord(13), Felipe C. Geyer(13), Kerry Fenwick(12), Alan Ashworth(11), Kay Savage(10), Caterina Marchiò(9), Radost Vatcheva(7), Anita Grigoriadis(7), David S.P. Tan(7), Charlotte K.Y. Ng(7), Anne Vincent‐Salomon(7), Rachel Brough(5), Andrew Tutt(5), Nicholas C. Turner(5), Maryou Lambros(5)